Nathalie Pellenkoft Shares of United Natural Foods ( UNFI ) are under heavy selling pressure into Tuesday’s open after the company realized softer sales and retail margin compression during its fiscal third quarter due to optimization efforts as part of the company’s “value creation strategy.” The company also saw its free cash flow cut in half to $54M as net cash provided by operating activities ...
Nathalie Pellenkoft Shares of United Natural Foods ( UNFI ) are under heavy selling pressure into Tuesday’s open after the company realized softer sales and retail margin compression during its fiscal third quarter due to optimization efforts as part of the company’s “value creation strategy.” The company also saw its free cash flow cut in half to $54M as net cash provided by operating activities dropped 43% amid higher working capital use that was only partially offset by increased profitability during the quarter. UNFI’s third quarter results included a 4.2% drop in sales while (adjusted) profitability improved 75% to $0.77 per share as unadjusted earnings swung to a profit from a loss in the same quarter last year. These results were in line to below expectations, respectively, also adding pressure to UNFI shares. The results led the company to narrow its guidance for the full year. UNFI now expects sales to be within a range of $31.1B to $31.3B, slightly less than $31.31B estimates. Adjusted EPS range was narrowed to $2.40 to $2.60 per share with a $2.50 midpoint that is also below estimates. The company maintained its free cash flow and capital expenditure forecasts at ~$330M and ~$250M, respectively. More on United Natural Foods United Natural Foods: The Danger Of Chasing A 'Shrink To Grow' Turnaround United Natural Foods: The Gains Should Continue, But Slow United Natural Foods, Inc. (UNFI) Presents at UBS Global Consumer and Retail Conference Transcript United Natural Foods Non-GAAP EPS of $0.77 in-line, revenue of $7.7B misses by $100M United Natural Foods Q3 2026 Earnings Preview
Allegiant Travel ( ALGT ) has begun a tender offer to buy back its outstanding $403M of senior secured notes due 2027 and is soliciting bondholder consent for amendments that would remove most restrictive covenants and modify certain default provisions. The tender offer and consent solicitation are subject to several conditions, including the successful completion of a planned debt financing, the ...
Allegiant Travel ( ALGT ) has begun a tender offer to buy back its outstanding $403M of senior secured notes due 2027 and is soliciting bondholder consent for amendments that would remove most restrictive covenants and modify certain default provisions. The tender offer and consent solicitation are subject to several conditions, including the successful completion of a planned debt financing, the company said. Allegiant Travel ( ALGT ) also reserves the right to extend, modify, or terminate either process at any time before the expiration deadline, subject to applicable law. More on Allegiant Travel Company Allegiant Travel Company 2026 Q1 - Results - Earnings Call Presentation Allegiant Travel Company (ALGT) Q1 2026 Earnings Call Transcript Allegiant: Airline Stocks Rise Amid US-Iran Conflict Optimism, But Challenges Remain (Rating Upgrade) These 10 mid-cap U.S. Industrial stocks trading at attractive valuations Spirit’s collapse sparks scramble for routes, slots, survival among budget airlines
Key PointsDespite saying companies are overspending on artificial intelligence (AI), Dalio has big investments in cloud providers Amazon, Alphabet, and Microsoft.
Key PointsDespite saying companies are overspending on artificial intelligence (AI), Dalio has big investments in cloud providers Amazon, Alphabet, and Microsoft.
Apple's Aura Is Starting To Crack Submitted by QTR's Fringe Finance Apple isn’t in trouble. The company still generates enormous amounts of cash, the iPhone remains one of the most successful consumer products ever created, and its business continues to grow. If you forced me to choose one ecosystem to live in for the next decade, I’d still probably choose Apple’s. But for the first time in a very...
Apple's Aura Is Starting To Crack Submitted by QTR's Fringe Finance Apple isn’t in trouble. The company still generates enormous amounts of cash, the iPhone remains one of the most successful consumer products ever created, and its business continues to grow. If you forced me to choose one ecosystem to live in for the next decade, I’d still probably choose Apple’s. But for the first time in a very long time, the company appears to be showing signs of something investors haven’t had to worry about for years: imperfection. And in a world where Apple is eventually dethroned as one of the best companies in human history, the fall from grace would start with the smallest of signs. The smallest aberrations. The smallest…imperfections. What made Apple special over the last two decades wasn’t necessarily its ability to invent products first. It was the company’s uncanny ability to enter markets late and still produce the best version of whatever it was building. The iPod wasn’t the first MP3 player, the iPhone wasn’t the first smartphone, and the Apple Watch wasn’t the first smartwatch. Apple repeatedly demonstrated that it could arrive after everyone else, simplify the experience, and ultimately dominate. That’s why the company’s recent stumbles are worth paying attention to. The first is artificial intelligence. In February of 2025, I wrote about a simple interaction I had with Siri while washing dishes . Curious about whether all the hype surrounding AI had finally filtered down into products I actually used, I asked my Apple HomePod a straightforward question: “How many days are in February?” Instead of answering, Siri informed me that it couldn’t help and offered to send web search results to my phone. So imagine my surprise when I asked Siri how many days were in the month of February, and she retorted: “I’m sorry, I can’t answer that right now. Here are some responses I found on the web. Would you like me to send them to your phone?” “Are you f**king kidding me?” I t...
tanyss/iStock via Getty Images I have been covering Astera Labs ( ALAB ) since September last year and started with a Sell call, then moved to a Hold as a lot of valuation excess had been removed. Both calls were based primarily on valuations and worked through a relatively cooler market from Q4 2025 till April 2026 happened. My Ratings on ALAB (Seeking Alpha) My last call not so long ago in March...
tanyss/iStock via Getty Images I have been covering Astera Labs ( ALAB ) since September last year and started with a Sell call, then moved to a Hold as a lot of valuation excess had been removed. Both calls were based primarily on valuations and worked through a relatively cooler market from Q4 2025 till April 2026 happened. My Ratings on ALAB (Seeking Alpha) My last call not so long ago in March was still a Hold , a stronger one, acknowledging the operational progress versus valuations, but wary of the stock pricing in 2027–28 growth too early. What has happened since is a stupendous ~180% rally, first due to beta in a market that rebounded sharply from the March lows. That in itself pushed the stock close to $200. And as the market strength held, Astera's own earnings showed a Q1 beat (with gross margin actually rising to ~76.4% despite the feared mix shift) and a strong Q2 guide (now showing 2026 as potentially de-risked with supply secured)—which catapulted the stock well above $300. My concerns on pricing in future growth too early still remain valid (and more valid now after the run-up), but relying on already stretched multiples as a gating variable was terribly wrong, with market conditions and Astera's progress both leading to an opportunity loss. Just recognizing Astera's improving fundamentals (below is a snippet from my March call ), but calling off a Buy on valuations proved wrong - Revenue visibility has also improved - one of the biggest positives in my view. Q4 highlighted more than 10 Scorpio X engagements, multiple hyperscaler design wins, and an AWS-linked multi-year warrant. This grounds forward revenue visibility from TAM narratives to real anchors. The 2026 revenue expectations also look reachable now. As it stands today, going by the framework of my March thesis. Astera should be a Sell. As I will show further in this analysis, the March thesis just got valuations wrong for a reason, and that burden has obviously gotten even larger. Even adju...
Andrii Dodonov TG Therapeutics ( TGTX ) on Tuesday announced the initiation of a potentially pivotal mid-stage trial for its lead asset, Briumvi, in myasthenia gravis, alongside encouraging early-stage trial data for an injectable formulation of the drug. Citing topline data, the biotech said that Briumvi, which is approved in the U.S. for the central nervous system disorder multiple sclerosis, re...
Andrii Dodonov TG Therapeutics ( TGTX ) on Tuesday announced the initiation of a potentially pivotal mid-stage trial for its lead asset, Briumvi, in myasthenia gravis, alongside encouraging early-stage trial data for an injectable formulation of the drug. Citing topline data, the biotech said that Briumvi, which is approved in the U.S. for the central nervous system disorder multiple sclerosis, reduced disease burden following subcutaneous administration in myasthenia gravis, an autoimmune disorder. The trial of 11 patients with AChR-antibody-positive MG indicated that subcutaneous Briumvi led to exposures at least equivalent to the intravenous form of the therapy and consistently reduced myasthenia gravis outcome measures from baseline. The injectable Briumvi was well tolerated, with a safety profile consistent with that of IV Briumvi, the North Carolina-based company added. “These encouraging results support continued development of BRIUMVI in MG and also mark an important milestone in expanding the potential utility of BRIUMVI beyond multiple sclerosis,” CEO Michael Weiss said. “We are also excited to initiate this potentially registration-directed Phase 2 study evaluating a novel sequential treatment approach in myasthenia gravis,” he added. The Phase 2 trial, designed to evaluate Briumvi in those who have previously responded to efgartigimod, an FDA-approved MG therapy marketed by Argenx ( ARGX ), is expected to enroll roughly 120 patients. More on TG Therapeutics TG Therapeutics: Phase 1 Results Of Subcutaneous Briumvi Are A De-Risking Event TG Therapeutics: 'Strong Buy' Amid BRIUMVI Expansion Win And Boosted 2026 Outlook TG Therapeutics, Inc. (TGTX) Q1 2026 Earnings Call Transcript TG Therapeutics rises on early-stage trial data for Briumvi injectable TG Therapeutics posts late-stage trial win for Briumvi single infusion regimen
Jeremy Edwards Financial markets may “test” Federal Reserve Chair Kevin Warsh in the early months of his tenure, according to TS Lombard, which argued that history showed new Fed leaders often face significant bouts of market volatility soon after taking office. In a note, the firm said Wall Street has long embraced the idea that markets “test” new Fed chairs, with previous transitions frequently ...
Jeremy Edwards Financial markets may “test” Federal Reserve Chair Kevin Warsh in the early months of his tenure, according to TS Lombard, which argued that history showed new Fed leaders often face significant bouts of market volatility soon after taking office. In a note, the firm said Wall Street has long embraced the idea that markets “test” new Fed chairs, with previous transitions frequently coinciding with sharp equity selloffs. TS Lombard cited historical examples including Alan Greenspan's appointment in 1987, which was followed by Black Monday; Jerome Powell's 2018 debut during the "Volmageddon" volatility shock; and Ben Bernanke's tenure, when the first signs of the global financial crisis emerged. Arthur Burns and Paul Volcker also faced major economic and market challenges shortly after taking office. However, the firm argued that many of these episodes were driven less by markets challenging new leadership and more by newly appointed Fed chairs adopting hawkish policy stances to establish their inflation-fighting credibility. "If Warsh wants to avoid this outcome, he can just do what Janet Yellen did and stay as dovish as possible," TS Lombard wrote, while warning that delaying policy tightening could instead raise the risk of a more significant bout of market volatility in 2027. More on markets Monthly Macro Monitor: Nothing To See Here There's Trouble Brewing In The Treasury Market Macro Insights: The 'Dangerous Market' Playbook, 1999 Redux, And Navigating RAMpocalypse US2Y hits a fresh 52-week high, extending the sharp 2026 yield rally Traders pricing in a rate hike by year end after jobs jump
Applied Digital ( APLD ) said its subsidiary, APLD ComputeCo 3, plans to offer $1.59B of senior secured notes due 2031 in a private debt offering , subject to market conditions. Shares rose over 10% premarket to $45.15. APLD ComputeCo 3 plans to use the proceeds from the debt offering to fund construction of 150-megawatt of critical IT load at the fourth building at Applied Digital's Polaris Forge...
Applied Digital ( APLD ) said its subsidiary, APLD ComputeCo 3, plans to offer $1.59B of senior secured notes due 2031 in a private debt offering , subject to market conditions. Shares rose over 10% premarket to $45.15. APLD ComputeCo 3 plans to use the proceeds from the debt offering to fund construction of 150-megawatt of critical IT load at the fourth building at Applied Digital's Polaris Forge 1 AI campus in North Dakota, repay a bridge loan provided by Goldman Sachs, set aside funds for debt-service reserves, and cover transaction-related expenses. More on Applied Digital Applied Digital: 1-Month Lease Gap Signals Aggressive Hyperscaler Demand Applied Digital: Massive Revenue Backlog Escalation Underway Applied Digital Just Hit 1GW Of Contracted Capacity - Why It Matters Biggest stock movers Tuesday: APLD, QCOM, and more Applied Digital jumps after landing 210 MW lease deal at its fifth 'AI Factory'
Tincorp Metals ( TIN:CA ) ( TINFF ) will officially change its name to Auro Metals effective June 11, 2026. The rebranding reflects the company’s increased focus on the Santa Barbara Gold-Copper Project in Ecuador’s Zamora Copper-Gold Belt. Beginning at market open on June 11, 2026, the company’s shares will trade on the TSX Venture Exchange under the new ticker AURO. The company’s OTC listing wil...
Tincorp Metals ( TIN:CA ) ( TINFF ) will officially change its name to Auro Metals effective June 11, 2026. The rebranding reflects the company’s increased focus on the Santa Barbara Gold-Copper Project in Ecuador’s Zamora Copper-Gold Belt. Beginning at market open on June 11, 2026, the company’s shares will trade on the TSX Venture Exchange under the new ticker AURO. The company’s OTC listing will change from TINFF to AURFF. The name change will not affect the company’s capitalization structure. More on Tincorp Metals Inc. Financial information for Tincorp Metals Inc.
Warren Buffett stepped down as CEO of Berkshire Hathaway (NYSE: BRK-B) on December 31, 2025, after six decades leading the conglomerate he transformed from a struggling textile mill into a $1 trillion empire. The “Oracle of Omaha” left his successor, Greg Abel, with a very concentrated portfolio: more than 65% of Berkshire’s $381 billion portfolio is ... Why a Passive Income Portfolio With 5 of Wa...
Warren Buffett stepped down as CEO of Berkshire Hathaway (NYSE: BRK-B) on December 31, 2025, after six decades leading the conglomerate he transformed from a struggling textile mill into a $1 trillion empire. The “Oracle of Omaha” left his successor, Greg Abel, with a very concentrated portfolio: more than 65% of Berkshire’s $381 billion portfolio is ... Why a Passive Income Portfolio With 5 of Warren Buffett’s Highest Yielding Stocks Is Genius